Luminopia's amblyopia treatment now includes patients aged 8 to 12, expanding its previous FDA approval for ages 4 to 7. The ...

The OcuMet Beacon is a proprietary, noninvasive tool for assessing retinal health. The company said it will be available on ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

D-150 is a potential backbone therapy that is designed to provide multi-year sustained delivery of anti-VEGF (aflibercept and ...

Shehzad Batliwala, DO, known to his patients as Dr. Shehz, appeared on the ASCRS Foundation Symposium, where he discussed ...

A novel vitrectomy device shows promising safety and efficacy in the targeted removal of symptomatic vitreous opacities in ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

Therini Bio reveals promising Phase 1a trial results for THN391, a potential breakthrough treatment for neurodegenerative ...

Alex Hacopian, MD, highlights how a recent ambispective study demonstrated strong visual acuity outcomes and patient ...